Indian sites fared better in USFDA inspections in recent years, says IPA

Quick Summary:

Indian pharma accounts for 20 per cent of the global exports of generics by volume and is thus considered a pharma powerhouse.

The share of Official Action Indicated (OAI) status issued after an USFDA inspection for Indian sites has fallen from 26 per cent in 2014 to 13 per cent in 2023.

Sudarshan Jain, secretary general of the IPA said, “Schedule M will be instrumental in elevating the quality of pharmaceutical manufacturing in India.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: India

Topics: Pharma companies Pharma manufacturing USFDA Indian companies

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-06-26 @ 22:49:06 (1 weeks ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 721 words

Reading Time: 5 minutes read

Sentences: 29 lines

Sentence Length: 25 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 21395431

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 222 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 3 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions